Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned.
Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
The combination of rituximab, bendamustine, and low-dose cytarabine is an effective induction regimen for elderly patients with mantle cell lymphoma.
Controlling indolent non-Hodgkin lymphoma remains a priority as it has the potential to transform to aggressive or high-grade lymphoma.
Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy.
The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types.
Imatinib continued to show dramatic overall survival benefits after nearly 11 years of follow-up despite crossover for patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.
Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.